Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI EAFE ETF (IEFA) vs Pfizer Inc (PFE) Price & Performance

iShares Core MSCI EAFE ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

iShares Core MSCI EAFE ETF vs Pfizer Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.91, while Pfizer Inc trades at $24.76 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

IEFAPFE
Sector
Broad Market / FactorHealth
52-Week High
$98.56$28.56
52-Week Low
$81.70$23.29
Market Cap
$141.06B
Volume
29,869,932
Enterprise Value
$191.72B
Dividend Yield
6.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI EAFE ETF

IEFA trades at $95.57, down 0.71% today amid a bearish technical signal. The ETF focuses on developed international equities excluding the U.S. and Canada, offering a 3.30% dividend yield with a low 0.07% expense ratio. Recent news highlights its role in diversification away from S&P 500 concentration risks. Key support and resistance levels are tightly clustered around $96-$97.

The outlook remains mixed; IEFA provides cost-effective exposure to stable international markets but faces headwinds from currency fluctuations and central bank policy shifts. Its bearish technical trend and neutral oscillators suggest near-term consolidation, while long-term investors may value its dividend income and geographic diversification benefits.

Pfizer Inc

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE